Guardant Health Raises $90.7 Million in Registered Direct Offering with Baillie Gifford
December 26, 2023
🌥️Trending News
Guardant Health ($NASDAQ:GH), a leading precision oncology company, recently raised $90.7 million in a Registered Direct Offering with Baillie Gifford, an international investment management company. The funding will be used to support product development and build out the commercial infrastructure for Guardant Health’s cancer diagnostics suite. With this new capital infusion, Guardant Health is now well positioned to expand its offerings and further improve outcomes for cancer patients. Baillie Gifford’s participation in the Registered Direct Offering is another example of its commitment to investing in innovative healthcare companies.
It is also a long-term investor in Guardant Health and has been a key supporter of the company since its founding seven years ago. With a strong commitment to innovation and patient care, Guardant Health is poised to continue providing cutting-edge solutions that can improve the lives of cancer patients around the world.
Price History
On Friday, GUARDANT HEALTH, a leading precision oncology company, announced the pricing of a registered direct offering with Baillie Gifford, a prominent investment management firm. GUARDANT HEALTH stock opened at $27.5 and closed at $28.8, representing a 5.3% increase from the previous closing price of 27.3. The new funds will help GUARDANT HEALTH further develop its precision oncology solutions, expand its capabilities, and provide resources to improve patient outcomes. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Guardant Health. More…
| Total Revenues | Net Income | Net Margin |
| 535.78 | -432.34 | -80.7% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Guardant Health. More…
| Operations | Investing | Financing |
| -337 | 247.42 | 389.12 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Guardant Health. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.8k | 1.57k | 1.93 |
Key Ratios Snapshot
Some of the financial key ratios for Guardant Health are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 25.5% | – | -79.9% |
| FCF Margin | ROE | ROA |
| -67.8% | -102.7% | -14.9% |
Analysis
As a financial analyst, GoodWhale has analyzed the financials of GUARDANT HEALTH. According to GoodWhale’s Star Chart, GUARDANT HEALTH is strong in growth, medium in asset and weak in dividend, profitability. With a low health score of 3/10 with regard to its cashflows and debt, GoodWhale concluded that GUARDANT HEALTH is less likely to safely ride out any crisis without the risk of bankruptcy. Therefore, GoodWhale classified GUARDANT HEALTH as a ‘cheetah’ company, which has achieved high revenue or earnings growth but is considered less stable due to lower profitability. Investors who are looking for high returns may be interested in such companies. However, due to the riskiness of the investment, these investors need to consider if they are ready to take on the risk of investing in a ‘cheetah’ company before making a decision. More…
Peers
The competition in the market for cancer detection and treatment is heating up. Guardant Health Inc, a leading player in the field, is up against some stiff competition from the likes of Aclaris Therapeutics Inc, Inoviq Ltd, and Biomark Diagnostics Inc. All these companies are vying for a share of the pie in this rapidly growing market. While Guardant Health Inc has a strong product portfolio and a good track record, its competitors are not far behind and are also making inroads into this market. It remains to be seen who will emerge victorious in this battle.
– Aclaris Therapeutics Inc ($NASDAQ:ACRS)
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of drugs for the treatment of dermatological and immuno-inflammatory diseases. The company’s lead product candidates include ATI-502 for the treatment of seborrheic keratosis, and ATI-501 for the treatment of vitiligo. Aclaris Therapeutics Inc has a market cap of 1.11B as of 2022, a Return on Equity of -25.42%.
– Inoviq Ltd ($ASX:IIQ)
Inoviq Ltd is a publicly traded company with a market capitalization of 50.61M as of 2022. The company’s return on equity (ROE) is -13.68%. Inoviq Ltd is engaged in the development and commercialization of innovative drugs and therapies. The company’s products are designed to improve the lives of patients with serious medical conditions. Inoviq’s products are available in more than 60 countries worldwide.
– Biomark Diagnostics Inc ($OTCPK:BMKDF)
Biomark Diagnostics Inc is a company that provides diagnostic testing services. The company has a market capitalization of 10.88 million as of 2022 and a return on equity of 179.57%. The company’s diagnostic testing services include tests for cancer, cardiovascular disease, and infectious diseases. Biomark Diagnostics Inc is headquartered in the United States.
Summary
Guardant Health has seen a surge in its stock price after announcing a $90.7 million registered direct offering with Baillie Gifford. This is a key indication of investor confidence in the company, thanks to its success in developing and commercializing non-invasive cancer detection technologies. With this new injection of capital, Guardant Health is likely to invest in further research and development, as well as expansion into new markets. The long-term potential for the company is promising, and investors should keep their eyes on the future performance of this innovative biotechnology company.
Related Posts
Recent Posts
